<p>在昨天发布的一份报告中，Evercore ISI 的 Gavin Clark-Gartner 对 Sarepta Therapeutics 维持了持有评级，目标价为 17.00 美元。</p>
<h3>在 TipRanks Premium 上享受 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Clark-Gartner 关注医疗保健行业，重点关注 AbbVie、Vera Therapeutics 和 Insmed 等股票。根据 TipRanks，Clark-Gartner 推荐股票的平均回报率为 25.6%，成功率为 66.67%。</p>
<p>Sarepta Therapeutics 的分析师共识为持有，目标价共识为 21.24 美元。</p>

Sarepta医疗

<p>Evercore ISI 的 Gavin Clark-Gartner 对 Sarepta Therapeutics 维持持有评级，目标价为 17.00 美元。这位覆盖医疗保健行业的分析师平均回报率为 25.6%，成功率为 66.67%。Sarepta 的分析师共识为持有，目标价共识为 21.24 美元</p>

<p>In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Hold rating on Sarepta Therapeutics, with a price target of $17.00.</p>
<div class="lb-trans"><p>在昨天发布的一份报告中，Evercore ISI 的 Gavin Clark-Gartner 对 Sarepta Therapeutics 维持了持有评级，目标价为 17.00 美元。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Clark-Gartner covers the Healthcare sector, focusing on stocks such as AbbVie, Vera Therapeutics, and Insmed. According to TipRanks, Clark-Gartner has an average return of 25.6% and a 66.67% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Clark-Gartner 关注医疗保健行业，重点关注 AbbVie、Vera Therapeutics 和 Insmed 等股票。根据 TipRanks，Clark-Gartner 推荐股票的平均回报率为 25.6%，成功率为 66.67%。</p>
</div><p>Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $21.24.</p>
<div class="lb-trans"><p>Sarepta Therapeutics 的分析师共识为持有，目标价共识为 21.24 美元。</p>
</div>

Evercore ISI 继续对 Sarepta Therapeutics（SRPT）维持持有评级